Maria E L, Line H D, Bara A D, et al. An updated review on primary signet ring cell carcinoma of the urinary bladder and report of a case[J]. Scand J Urol, 2018, 52(2): 87-93.
[2]
Hamakawa T, Kojima Y, Naiki T, et al. Long-term survival of a patient with invasive signet ring cell carcinoma of the urinary bladder managed by combined S-1 and cisplatin adjuvant chemotherapy[J]. Case Rep Urol, 2013, 42(6): 915-919.
[3]
Pugashetti N, Yap S A, Lara P N Jr, et al. Metastatic signet ring cell carcinoma of the urinary bladder:a novel management approach to a rare tumor[J]. Can Urol Assoc J, 2015, 21(9): E204-E207.
[4]
Wang J, Wang F, Kessinger A. The impact of signet ring cell carcinoma histology on bladder cancer outcome[J].World J Urol, 2012, 30(10): 777-783.
[5]
Knollman H, Godwin J L, Jain R, et al. Muscle-invasive urothelial bladder cancer: an update on systemic therapy[J]. Ther Adv Urol, 2015, 7(5): 312-330.
[6]
Humphrey P A, Moch H, Cubilla A L, et al. The 2016 WHO classification of tumors of the urinary system and male genital organs-part B: prostate and bladder tumors[J]. Eur Urol, 2016, 70(2): 106-119.
[7]
El Ammari J E, Ahsani M, Riyach O, et al.Primary signet ring cell carcinoma of the urinary bladder successfully managed with cisplatin and gemcitabine: a case report[J]. J Med Case Rep, 2013, 7(1):37-42.
[8]
Thomas A A, Stephenson A J, Campbell S C, et al. Clinicopathologic features and utility of immunohistochemical markers in signet ring cell adenocarcinoma of the bladder[J].Hum Pathol,2009,40(2):108-116.
[9]
Gopalan V, Smith R A, Ho Y H, et al. Signet ring cell carcinoma of colorectum-current perspectives and molecular biology[J]. Int J Colorectal Dis, 2011, 26(2):127-133.
[10]
Singh J, Zherebitskiy V, Grynspan D, et al. Metastatic signet ring cell adenocarcinoma of the bladder:responsive to treatment?[J]. Can Urol Assoc J, 2012, 6(1): E15-E19.
[11]
Terada T. Primary pure signet ring cell adenocarcinoma of the urinary bladder: a report of three cases with an immunohistochemical study[J]. Med Oncol, 2012, 29(11): 2866-2869.
[12]
Wang J, Wang F W. Clinical characteristics and outcomes of patients with primary signet ring cell carcinoma of the urinary bladder[J]. Urol Int, 2011, 86(7): 453-460.
[13]
Cabibi D, Calascibetta A, Aragona F, et al. Differing expression of metalloprotease and of adhesion molecules in signet ring cell and intestinal colorectal carcinoma[J]. Anticancer Res, 2009, 29(12):4417-4422.
[14]
Lim M G, Adsay N V, Grignon D J, et al. E-cadherin expression in plasmacytoid, signet ring cell and micropapillary variants of urothelial carcinoma: comparison with usual-type high-grade urothelial carcinoma[J]. Mod Pathol, 2011, 24(5): 241-247.
[15]
Akamatsu S, Takahashi A, Ito M, et al. Primary signet-ring cell carcinoma of the urinary bladder[J]. Urology, 2010,75(10): 615-618.
[16]
Farzad A, Morteza F K, Yalda N, et al. Primary signet ring cell carcinoma of the urinary bladder successfully managed with radical cystectomy in a young patient[J]. Case Rep Urol, 2017,28(4): 91-101.
Dadhania V, Czerniak B, Guo C C. Adenocarcinoma of the urinary bladder[J].Am J Clin Exp Urol,2015, 3(2):51-63.
[19]
Jayarajah U, Hilary D M, Herath K B, et al. Primary signet ring cell adenocarcinoma of the urinary bladder treated with partial cystectomy: a case report and review of the literature[J]. Case Rep Urol, 2017, 21(8): 682-689.
Boukettaya W, Feki J, Charfi S, et al. Primary signet ring cell adenocarcinoma of the urinary bladder: a report of 2 cases[J].Case Rep Urol, 2014, 26(2): 85-87.
Postow M A, Callahan M K, Wolchok J D. Immune checkpoint blockade in cancer therapy[J]. J Clin Oncol, 2015, 33(11): 1974-1982.
[24]
Toplalian S L, Drake C G, Et Pardoll D M. Immune checkpoint blockade: a common denominator approach to cancer therapy[J]. Cander Cell, 2015, 27(6):450-461.
2021, Vol. 32 
